Stockreport

BioMarin Pharmaceutical Inc. (BMRN) Rated Overweight at Wells Fargo Despite Voxzogo Phase 2 Study Discontinuations [Yahoo! Finance]

BioMarin Pharmaceutical Inc.  (BMRN) 
Last biomarin pharmaceutical inc. earnings: 4/29 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.biomarin.com
PDF TheFly reported on March 16 that Wells Fargo maintained an Overweight rating on BMRN with a $75 price target. The firm noted that BioMarin discontinued three Phase 2 Vo [Read more]